What is Cellebrite Di Ltd's earnings per share (EPS)?

Cellebrite Di Ltd (CLBT) reported diluted earnings per share of $0.31 for fiscal year 2025. This represents a 123.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cellebrite Di Ltd Financials

CLBT

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows Cellebrite Di Ltd (CLBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLBT FY2025 2026-04-22

High gross margins and strong cash conversion show a high-margin model whose operating scale is funding heavy reinvestment.

As operating margin rose from 10.2% to 14.0%, free cash flow margin also stayed unusually high, so the big swing in reported net income looks less like a collapse in the core engine than noise around it. That is reinforced by cash falling to $124M even after $174M of operating cash flow, which indicates capital was deployed into investing activity rather than consumed by operations.

Gross margin held near 84.0% while R&D spending reached $114M, so expansion was not coming from starving product investment. That combination means reinvestment discipline and unit economics were improving together.

Receivables were only $105M against revenue of $476M, and inventory remained tiny, which points to an asset-light model with little cash trapped in stock. Liquidity is still adequate at 1.6x, but cash is lower than a year earlier because the balance sheet is being used more actively for investment.

Financial Health Signals

Financial Health Score 68/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cellebrite Di Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Cellebrite Di Ltd has an operating margin of 14.0%, meaning the company retains $14 of operating profit per $100 of revenue. This strong profitability earns a score of 68/100, reflecting efficient cost management and pricing power. This is down from 14.2% the prior year.

Growth

Cellebrite Di Ltd's revenue surged 18.6% year-over-year to $475.7M, reflecting rapid business expansion. This strong growth earns a score of 83/100.

Leverage

Cellebrite Di Ltd has a moderate D/E ratio of 0.94. This balance of debt and equity financing earns a leverage score of 48/100.

Liquidity

Cellebrite Di Ltd's current ratio of 1.56 indicates adequate short-term liquidity, earning a score of 43/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Cellebrite Di Ltd converts 33.7% of revenue into free cash flow ($160.3M). This strong cash generation earns a score of 95/100.

Returns

Cellebrite Di Ltd earns a strong 16.2% return on equity (ROE), meaning it generates $16 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 69/100. This is up from -84.2% the prior year.

Altman Z-Score Safe

6.19

Cellebrite Di Ltd scores 6.19, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.0B) relative to total liabilities ($454.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Cellebrite Di Ltd passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.22x

For every $1 of reported earnings, Cellebrite Di Ltd generates $2.22 in operating cash flow ($173.5M OCF vs $78.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$475.7M

YoY+18.6%

5Y CAGR+19.5%

Cellebrite Di Ltd generated $475.7M in revenue in fiscal year 2025. This represents an increase of 18.6% from the prior year.

EBITDA

$78.3M

YoY+16.0%

5Y CAGR+39.0%

Cellebrite Di Ltd's EBITDA was $78.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.0% from the prior year.

Net Income

$78.3M

YoY+127.7%

5Y CAGR+68.4%

Cellebrite Di Ltd reported $78.3M in net income in fiscal year 2025. This represents an increase of 127.7% from the prior year.

EPS (Diluted)

$0.31

YoY+123.0%

Cellebrite Di Ltd earned $0.31 per diluted share (EPS) in fiscal year 2025. This represents an increase of 123.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$160.3M

YoY+29.7%

5Y CAGR+21.6%

Cellebrite Di Ltd generated $160.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.7% from the prior year.

Cash & Debt

$124.5M

YoY-35.1%

5Y CAGR-1.4%

Cellebrite Di Ltd held $124.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

249M

YoY+6.0%

5Y CAGR+14.8%

Cellebrite Di Ltd had 249M shares outstanding in fiscal year 2025. This represents an increase of 6.0% from the prior year.

Margins & Returns

Gross Margin

84.2%

YoY-0.2pp

5Y CAGR+3.6pp

Cellebrite Di Ltd's gross margin was 84.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the prior year.

Operating Margin

14.0%

YoY-0.2pp

5Y CAGR+9.3pp

Cellebrite Di Ltd's operating margin was 14.0% in fiscal year 2025, reflecting core business profitability. This is down 0.2 percentage points from the prior year.

Net Margin

16.5%

YoY+87.0pp

5Y CAGR+13.5pp

Cellebrite Di Ltd's net profit margin was 16.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 87.0 percentage points from the prior year.

Return on Equity

16.2%

YoY+100.4pp

5Y CAGR+7.1pp

Cellebrite Di Ltd's ROE was 16.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 100.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$113.9M

YoY+15.7%

5Y CAGR+15.9%

Cellebrite Di Ltd invested $113.9M in research and development in fiscal year 2025. This represents an increase of 15.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$13.2M

YoY+54.4%

5Y CAGR+16.4%

Cellebrite Di Ltd invested $13.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.4% from the prior year.

CLBT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$475.7M+18.6%	$401.2M+23.4%	$325.1M+20.1%	$270.7M+9.9%	$246.2M+26.3%	$194.9M
Cost of Revenue	$75.2M+20.1%	$62.6M+17.6%	$53.2M+4.9%	$50.7M+19.2%	$42.6M+12.3%	$37.9M
Gross Profit	$400.5M+18.3%	$338.6M+24.5%	$271.9M+23.6%	$219.9M+8.0%	$203.7M+29.7%	$157.0M
R&D Expenses	$113.9M+15.7%	$98.4M+16.6%	$84.4M+4.7%	$80.6M+23.0%	$65.5M+20.5%	$54.4M
SG&A Expenses	$65.3M+28.4%	$50.9M+17.2%	$43.4M+6.3%	$40.9M-14.8%	$47.9M+49.2%	$32.1M
Operating Income	$66.5M+16.8%	$56.9M+71.2%	$33.2M+3083.6%	$1.0M-92.4%	$13.8M+49.9%	$9.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$12.4M+75.9%	$7.0M+26.8%	$5.5M+12404.4%	-$45K-100.4%	$10.9M+94.2%	$5.6M
Net Income	$78.3M+127.7%	-$283.0M-249.0%	-$81.1M-167.1%	$120.8M+69.2%	$71.4M+1135.0%	$5.8M
EPS (Diluted)	$0.31+123.0%	$-1.35-214.0%	$-0.43-172.9%	$0.59+34.1%	$0.44+650.0%	$-0.08

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLBT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$938.9M+36.0%	$690.6M+29.6%	$532.9M+32.1%	$403.3M+18.7%	$339.8M-6.8%	$364.4M
Current Assets	$575.9M+1.5%	$567.6M+34.5%	$422.1M+42.6%	$295.9M+8.3%	$273.2M-15.7%	$324.3M
Cash & Equivalents	$124.5M-35.1%	$191.7M+1.1%	$189.5M+116.2%	$87.6M-40.0%	$146.0M+9.1%	$133.8M
Inventory	$7.6M-14.9%	$8.9M-10.1%	$9.9M-2.3%	$10.2M+56.3%	$6.5M+37.0%	$4.8M
Accounts Receivable	$105.0M+27.5%	$82.4M+6.6%	$77.3M-1.9%	$78.8M+16.7%	$67.5M+1.8%	$66.3M
Goodwill	$119.6M+316.4%	$28.7M+7.0%	$26.8M0.0%	$26.8M0.0%	$26.8M+183.5%	$9.5M
Total Liabilities	$454.5M+28.2%	$354.5M-28.9%	$498.7M+51.4%	$329.4M-20.3%	$413.1M+37.4%	$300.6M
Current Liabilities	$369.7M+25.1%	$295.5M+16.4%	$253.8M+22.2%	$207.8M+11.4%	$186.6M+17.1%	$159.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$484.3M+44.1%	$336.0M+882.2%	$34.2M-53.7%	$73.9M+200.7%	-$73.3M-215.0%	$63.8M
Retained Earnings	-$86.5M+47.5%	-$164.9M-239.5%	$118.1M-40.7%	$199.2M+154.0%	$78.4M+176.8%	$28.3M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$938.9M+19.2%	$787.4M+14.0%	$690.6M+24.1%	$556.6M+4.4%	$532.9M+25.1%	$425.9M+5.6%	$403.3M+24.2%	$324.8M
Current Assets	$575.9M-5.0%	$606.1M+6.8%	$567.6M+36.9%	$414.8M-1.7%	$422.1M+25.1%	$337.4M+14.0%	$295.9M+26.7%	$233.6M
Cash & Equivalents	$124.5M-30.6%	$179.2M-6.5%	$191.7M+79.2%	$107.0M-43.6%	$189.5M+71.5%	$110.5M+26.1%	$87.6M-4.4%	$91.7M
Inventory	$7.6M-20.3%	$9.5M+6.7%	$8.9M+1.8%	$8.8M-11.6%	$9.9M-8.2%	$10.8M+6.3%	$10.2M+25.4%	$8.1M
Accounts Receivable	$105.0M+12.7%	$93.1M+13.1%	$82.4M+65786.4%	$125K-99.8%	$77.3M+68890.2%	$112K-99.9%	$78.8M	N/A
Goodwill	$119.6M+316.4%	$28.7M0.0%	$28.7M+7.0%	$26.8M0.0%	$26.8M0.0%	$26.8M0.0%	$26.8M0.0%	$26.8M
Total Liabilities	$454.5M+19.9%	$379.0M+6.9%	$354.5M-40.6%	$596.7M+19.7%	$498.7M+22.1%	$408.3M+24.0%	$329.4M+9.5%	$300.8M
Current Liabilities	$369.7M+19.3%	$310.0M+4.9%	$295.5M+24.6%	$237.2M-6.5%	$253.8M+24.1%	$204.5M-1.6%	$207.8M+20.2%	$172.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$484.3M+18.6%	$408.4M+21.5%	$336.0M+936.7%	-$40.2M-217.4%	$34.2M+94.9%	$17.6M-76.2%	$73.9M+207.0%	$24.1M
Retained Earnings	-$86.5M+32.4%	-$128.0M+22.4%	-$164.9M-818.0%	$23.0M-80.6%	$118.1M-6.5%	$126.3M-36.6%	$199.2M+19.3%	$167.1M

CLBT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$173.5M+31.3%	$132.2M+29.5%	$102.1M+396.0%	$20.6M-42.9%	$36.1M-45.8%	$66.5M
Capital Expenditures	$13.2M+54.4%	$8.6M+63.8%	$5.2M-24.2%	$6.9M+34.9%	$5.1M-17.3%	$6.2M
Free Cash Flow	$160.3M+29.7%	$123.6M+27.7%	$96.8M+607.8%	$13.7M-55.8%	$30.9M-48.7%	$60.3M
Investing Cash Flow	-$268.3M-79.5%	-$149.5M-563.1%	-$22.5M+75.3%	-$91.2M-301.7%	$45.2M+801.3%	-$6.4M
Financing Cash Flow	$25.1M+21.3%	$20.7M-5.1%	$21.8M+55.8%	$14.0M+120.4%	-$68.4M-696.0%	-$8.6M
Dividends Paid	N/A	N/A	$0	$0-100.0%	$100.0M+900.0%	$10.0M
Share Buybacks	N/A	N/A	N/A	$0	$0-100.0%	$85K

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLBT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	84.2%-0.2pp	84.4%+0.8pp	83.6%+2.4pp	81.3%-1.5pp	82.7%+2.2pp	80.6%
Operating Margin	14.0%-0.2pp	14.2%+4.0pp	10.2%+9.8pp	0.4%-5.2pp	5.6%+0.9pp	4.7%
Net Margin	16.5%+87.0pp	-70.5%-45.6pp	-24.9%-69.6pp	44.6%+15.6pp	29.0%+26.0pp	3.0%
Return on Equity	16.2%+100.4pp	-84.2%+152.8pp	-237.0%-400.6pp	163.5%	N/A	9.1%
Return on Assets	8.3%+49.3pp	-41.0%-25.8pp	-15.2%-45.2pp	29.9%+8.9pp	21.0%+19.4pp	1.6%
Current Ratio	1.56-0.4	1.92+0.3	1.66+0.2	1.42-0.0	1.46-0.6	2.03
Debt-to-Equity	0.94-0.1	1.06-13.5	14.58+10.1	4.46+10.1	-5.63-10.3	4.71
FCF Margin	33.7%+2.9pp	30.8%+1.0pp	29.8%+24.7pp	5.1%-7.5pp	12.6%-18.4pp	30.9%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.56-0.4	1.96+0.0	1.92+0.2	1.75+0.1	1.66+0.0	1.65+0.2	1.42+0.1	1.35
Debt-to-Equity	0.94+0.0	0.93-0.1	1.06+15.9	-14.86-29.4	14.58-8.7	23.26+18.8	4.46-8.0	12.50
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Box Inc BOX

$4.0B

Calix Networks CALX

$2.5B

Paymentus Holdings Inc PAY

$3.6B

Avepoint Inc. AVPT

$2.7B

Qualys Inc QLYS

$5.6B

Frequently Asked Questions

What is Cellebrite Di Ltd's annual revenue?

Cellebrite Di Ltd (CLBT) reported $475.7M in total revenue for fiscal year 2025. This represents a 18.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cellebrite Di Ltd's revenue growing?

Cellebrite Di Ltd (CLBT) revenue grew by 18.6% year-over-year, from $401.2M to $475.7M in fiscal year 2025.

Is Cellebrite Di Ltd profitable?

Yes, Cellebrite Di Ltd (CLBT) reported a net income of $78.3M in fiscal year 2025, with a net profit margin of 16.5%.

What is Cellebrite Di Ltd's EBITDA?

Cellebrite Di Ltd (CLBT) had EBITDA of $78.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cellebrite Di Ltd's gross margin?

Cellebrite Di Ltd (CLBT) had a gross margin of 84.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cellebrite Di Ltd's operating margin?

Cellebrite Di Ltd (CLBT) had an operating margin of 14.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cellebrite Di Ltd's net profit margin?

Cellebrite Di Ltd (CLBT) had a net profit margin of 16.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cellebrite Di Ltd's return on equity (ROE)?

Cellebrite Di Ltd (CLBT) has a return on equity of 16.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cellebrite Di Ltd's free cash flow?

Cellebrite Di Ltd (CLBT) generated $160.3M in free cash flow during fiscal year 2025. This represents a 29.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellebrite Di Ltd's operating cash flow?

Cellebrite Di Ltd (CLBT) generated $173.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cellebrite Di Ltd's total assets?

Cellebrite Di Ltd (CLBT) had $938.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cellebrite Di Ltd's capital expenditures?

Cellebrite Di Ltd (CLBT) invested $13.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cellebrite Di Ltd spend on research and development?

Cellebrite Di Ltd (CLBT) invested $113.9M in research and development during fiscal year 2025.

How many shares does Cellebrite Di Ltd have outstanding?

Cellebrite Di Ltd (CLBT) had 249M shares outstanding as of fiscal year 2025.

What is Cellebrite Di Ltd's current ratio?

Cellebrite Di Ltd (CLBT) had a current ratio of 1.56 as of fiscal year 2025, which is generally considered healthy.

What is Cellebrite Di Ltd's debt-to-equity ratio?

Cellebrite Di Ltd (CLBT) had a debt-to-equity ratio of 0.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellebrite Di Ltd's return on assets (ROA)?

Cellebrite Di Ltd (CLBT) had a return on assets of 8.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cellebrite Di Ltd's Altman Z-Score?

Cellebrite Di Ltd (CLBT) has an Altman Z-Score of 6.19, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cellebrite Di Ltd's Piotroski F-Score?

Cellebrite Di Ltd (CLBT) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellebrite Di Ltd's earnings high quality?

Cellebrite Di Ltd (CLBT) has an earnings quality ratio of 2.22x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cellebrite Di Ltd?

Cellebrite Di Ltd (CLBT) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.